Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Sarepta Therapeutics Inc (NASDAQ: SRPT) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Sarepta Therapeutics Inc (NASDAQ: SRPT)  concerning whether a series of statements by Sarepta Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On January 15, 2016, the U.S. Food and Drug Administration released a statement by an agency advisory committee that placed doubt on the approval prospects of Sarepta's muscular dystrophy drug eteplirsen. The agency's internal evaluatation of eteplirsen stated, in part, that "[a]lthough FDA is prepared to be flexible with respect to a devastating illness with no treatment options, we cannot approve drugs for which substantial evidence of effectiveness has not been established."

On this news, NASDAQ: SRPT stock declined nearly 58 percent on January 15, 2016 during intraday trading.

Based in Cambridge, Massachusetts, and founded in 1980 Sarepta Therapeutics Inc is a biopharmaceutical company, focusing on development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases.

If you purchased shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) on or before On January 15, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185